Anti-Mouse CXCL5

Purified Recombinant Mouse LIX (>98%)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: Measured by its ability to neutralize LIX-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR2. The Neutralization Dose (ND₅₀) is typically 1-5 µg/mL in the presence of 0.2 µg/mL Recombinant Mouse LIX.

Goat Anti-Mouse CXCL5 recognizes Mouse CXCL5. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

CXCL5 is an inflammatory chemokine that belongs to the CXC chemokine family¹ that has a role in the development of cardiovascular diseases.² CXCL5 is expressed by fibroblasts, is induced by bacterial lipopolysaccharides, and is chemotactic for neutrophils.¹ It is expressed by epithelial cells within colorectal mucosa is a chemoattractant for neutrophils and has been implicated in Crohn's disease and ulcerative colitis.³ CXCL5 is important in growth and development of colorectal cancer, implicating a future role in both cancer therapy and diagnosis.⁴

1. Rajashekhar, G et al. (2007) Physiol Genomics 31: 104
2. Mahsa, M et al. (2008) Molec Diagnosis & Therapy 12: 391
3. Wågsäter, D. et al. (2007) International J Oncol. 31: 97
4. Nagelkerke, F. et al. (2008) Clinical Cancer Research 14: 2276